316 related articles for article (PubMed ID: 15674856)
1. Breast carcinoma chemoprevention in the community setting. Estimating risks and benefits.
Brewster AM; Christo DK; Lai H; Helzlsouer K
Cancer; 2005 Mar; 103(6):1147-53. PubMed ID: 15674856
[TBL] [Abstract][Full Text] [Related]
2. Decision analysis of tamoxifen for the prevention of invasive breast cancer.
Grann VR; Sundararajan V; Jacobson JS; Whang W; Heitjan DF; Antman KH; Neugut AI
Cancer J; 2000; 6(3):169-78. PubMed ID: 10882333
[TBL] [Abstract][Full Text] [Related]
3. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.
Melnikow J; Paterniti D; Azari R; Kuenneth C; Birch S; Kuppermann M; Nuovo J; Keyzer J; Henderson S
Cancer; 2005 May; 103(10):1996-2005. PubMed ID: 15825209
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy.
Veronesi U; Maisonneuve P; Rotmensz N; Bonanni B; Boyle P; Viale G; Costa A; Sacchini V; Travaglini R; D'Aiuto G; Oliviero P; Lovison F; Gucciardo G; del Turco MR; Muraca MG; Pizzichetta MA; Conforti S; Decensi A;
J Natl Cancer Inst; 2007 May; 99(9):727-37. PubMed ID: 17470740
[TBL] [Abstract][Full Text] [Related]
5. Acceptance of tamoxifen chemoprevention by physicians and women at risk.
Tchou J; Hou N; Rademaker A; Jordan VC; Morrow M
Cancer; 2004 May; 100(9):1800-6. PubMed ID: 15112259
[TBL] [Abstract][Full Text] [Related]
6. The cost effectiveness of tamoxifen in the prevention of breast cancer.
Noe LL; Becker RV; Gradishar WJ; Gore M; Trotter JP
Am J Manag Care; 1999 Jun; 5(6 Suppl):S389-406. PubMed ID: 10538851
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer risk in primary care: implications for chemoprevention.
Lewis CL; Kinsinger LS; Harris RP; Schwartz RJ
Arch Intern Med; 2004 Sep; 164(17):1897-903. PubMed ID: 15451765
[TBL] [Abstract][Full Text] [Related]
9. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
Beattie MS; Costantino JP; Cummings SR; Wickerham DL; Vogel VG; Dowsett M; Folkerd EJ; Willett WC; Wolmark N; Hankinson SE
J Natl Cancer Inst; 2006 Jan; 98(2):110-5. PubMed ID: 16418513
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention Indication Score: a user-friendly tool for prevention of breast cancer - pilot analysis.
Layeequr Rahman R; Crawford S
Breast; 2009 Oct; 18(5):289-93. PubMed ID: 19716702
[TBL] [Abstract][Full Text] [Related]
11. [Italian study on the chemoprevention of breast cancer with tamoxifen].
Veronesi U; Costa A; Sacchini V; Luini A; Bonanni B; Veronesi P; Rotmensz N; Boyle P
Contracept Fertil Sex; 1995 Apr; 23(4):258-60. PubMed ID: 7757133
[TBL] [Abstract][Full Text] [Related]
12. Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use.
Cuenca RE; Giachino J; Arredondo MA; Hempling R; Edge SB
Cancer; 1996 May; 77(10):2058-63. PubMed ID: 8640670
[TBL] [Abstract][Full Text] [Related]
13. Reducing the risk of breast cancer with tamoxifen in women at increased risk.
Vogel VG
J Clin Oncol; 2001 Sep; 19(18 Suppl):87S-92S. PubMed ID: 11560980
[TBL] [Abstract][Full Text] [Related]
14. Physician recommendations regarding tamoxifen and patient utilization of tamoxifen after surgery for ductal carcinoma in situ.
Yen TW; Hunt KK; Mirza NQ; Thomas ES; Singletary SE; Babiera GV; Meric-Bernstam F; Buchholz TA; Feig BW; Ross MI; Ames FC; Theriault RL; Kuerer HM
Cancer; 2004 Mar; 100(5):942-9. PubMed ID: 14983489
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina.
Bradbury BD; Lash TL; Kaye JA; Jick SS
Cancer; 2005 Mar; 103(6):1114-21. PubMed ID: 15712362
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer risks and prevention: implications of the Breast Cancer Prevention Trial results.
Crowell EB; Jubelirer SJ
W V Med J; 2000; 96(6):598-601. PubMed ID: 11194088
[TBL] [Abstract][Full Text] [Related]
17. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J
Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680
[TBL] [Abstract][Full Text] [Related]
18. Risks, benefits, and effects on quality of life of selective estrogen-receptor modulator therapy in postmenopausal women at increased risk of breast cancer.
Ganz PA; Land SR
Menopause; 2008; 15(4 Suppl):797-803. PubMed ID: 18596601
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen for breast cancer prevention: a framework for clinical decisions.
Cykert S; Phifer N; Hansen C
Obstet Gynecol; 2004 Sep; 104(3):433-42. PubMed ID: 15339751
[TBL] [Abstract][Full Text] [Related]
20. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
Li CI; Malone KE; Saltzman BS; Daling JR
Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
